Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
People who received a shortened course of antiviral therapy were less likely to be cured.
Timely testing and treatment could improve outcomes for young people who inject drugs.
Cirrhosis severity and CD4 cell counts were linked to a greater chance of developing liver cancer.
Louisiana saw a bump-up in HCV prescriptions after the alternate model was introduced.
People treated with direct-acting antivirals had better overall survival than those whose hepatitis C remained untreated.
Barriers still stand in the way of making treatment available to all who need it.
Disruptions in access to treatment and harm reduction services could set back effort to eliminate hep C in the U.S.
However, some 10% experienced liver decompensation even after antiviral therapy.
The Epclusa and Mavyret combination pills are now indicated for kids as young as age 3.
Assessing patient-reported outcomes can support treatment for hard-to-reach populations.
People who received treatment had a lower composite risk of cirrhosis, liver cancer and death.
Based on surveys conducted in 2015 and 2018, the number appears to have nearly tripled in San Francisco.
Among people treated for hepatitis C, diabetes and chronic kidney disease were both linked to a higher risk of cardiovascular death.
HIV advocate Lepena Reid is living free of hepatitis C.
A guide to the key aspects of today’s most effective hep C therapies
Despite limited testing and clinical visits, 95% of the study population was able to achieve a sustained virological response.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.